Last reviewed · How we verify
Azilsartan tablets
Azilsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.
Azilsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Hypertension.
At a glance
| Generic name | Azilsartan tablets |
|---|---|
| Sponsor | Lee's Pharmaceutical Limited |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Azilsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues. By blocking angiotensin II signaling, it causes vasodilation and reduces aldosterone secretion, leading to decreased blood pressure and reduced sodium retention. This mechanism makes it effective for hypertension management and cardiovascular protection.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Diarrhea
- Hyperkalemia
- Hypotension
Key clinical trials
- A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure
- Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia) (PHASE1)
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
- Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.
- A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension (PHASE3)
- A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants (PHASE1)
- International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azilsartan tablets CI brief — competitive landscape report
- Azilsartan tablets updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI